Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | LDHA | P00338 | 1/20 | 0.36 |
| ▸ | LDHB | P07195 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL715193 | 0.95 | — | — | |
| SCHEMBL6518958 | 0.95 | — | — | |
| Water SCHEMBL10863045 | 0.95 | CA1 (0.40) | CA1CA2CA9LDHALDHB | |
| Water SCHEMBL27791587 | 0.90 | CA1 (0.36) | CA1CA2CA9LDHALDHB | |
| Water SCHEMBL27701356 | 0.90 | CA1 (0.36) | CA1CA2CA9LDHALDHB | |
| SCHEMBL1122402 | 0.89 | CA1 (0.44) | CA1CA2CA9LDHALDHB | |
| SCHEMBL28953 | 0.89 | — | — | |
| Ammonia Solution, Strong SCHEMBL27770412 | 0.86 | LDHA (0.33) | CA1CA2CA9LDHALDHB | |
| Water SCHEMBL27781425 | 0.86 | LDHA (0.33) | CA1CA2CA9LDHALDHB | |
| Hydrochloric Acid SCHEMBL11010496 | 0.84 | CA1 (0.40) | CA1CA2CA9LDHALDHB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611878-A2 | SILICON POLISHING COMPOSITIONS WITH HIGH RATE AND LOW DEFECTIVITY | Cabot Microelectronics Corporation (US) | 2013-07-10 | — | — | EP | claimed |
| US-8273142-B2 | Silicon polishing compositions with high rate and low defectivity | CABOT MICROELECTRONICS CORPORATION (US) | 2012-09-25 | — | — | US | claimed |
| US-20120058642-A1 | Silicon polishing compositions with high rate and low defectivity | CMC MATERIALS LLC | 2012-03-08 | — | — | US | claimed |
| WO-2012030752-A2 | SILICON POLISHING COMPOSITIONS WITH HIGH RATE AND LOW DEFECTIVITY | CABOT MICROELECTRONICS CORPORATION (US) | 2012-03-08 | — | — | WO | claimed |
| US-20240191365-A1 | METAL COMPOUND BASED CATALYSTS FOR ELECTROSYNTHESIS OF HYDROGEN PEROXIDE AND LINEAR PAIRED ELECTROCHEMICAL VALORIZATION OF BIOMASS-DERIVED FEEDSTOCKS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2024-06-13 | — | — | US | disclosed |
| US-10446852-B2 | Fuel-cell system and method of generating energy from crude fuel | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-9908819-B1 | Printing method for production a ceramic green body | WZR ceramic solutions GmbH (DE) | 2018-03-06 | — | — | US | disclosed |
| US-20170263945-A1 | FUEL-CELL SYSTEM AND METHOD OF GENERATING ENERGY FROM CRUDE FUEL | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2017-09-14 | — | — | US | disclosed |
| US-9683123-B2 | Silver ink | PESOLVE CO., LTD. (KR) | 2017-06-20 | — | — | US | disclosed |
| US-20160168408-A1 | SILVER INK | PESOLVE CO., LTD. (KR) | 2016-06-16 | — | — | US | disclosed |
| EP-2611878-A2 | SILICON POLISHING COMPOSITIONS WITH HIGH RATE AND LOW DEFECTIVITY | Cabot Microelectronics Corporation (US) | 2013-07-10 | — | — | EP | disclosed |
| US-8309552-B2 | Immunomodulating heterocyclic compounds | MEDIGENE AG (DE) | 2012-11-13 | — | — | US | disclosed |
| EP-1603917-B1 | IMMUNOMODULATING HETEROCYCLIC COMPOUNDS | MEDIGENE LTD (GB) | 2010-11-24 | — | — | EP | disclosed |
| US-20090312334-A1 | Immunomodulating Heterocyclic Compounds | MEDIGENE LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| US-7598247-B2 | Immunomodulating heterocyclic compounds | MEDIGENE LIMITED (GB) | 2009-10-06 | — | — | US | disclosed |
| US-20080045527-A1 | Immunomodulating Heterocyclic Compounds | MEDIGENE LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
| US-7276505-B2 | Immunomodulating heterocyclic compounds | MEDIGENE LIMITED (GB) | 2007-10-02 | — | — | US | disclosed |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | AVIDEX LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| EP-1603917-A1 | IMMUNOMODULATING HETEROCYCLIC COMPOUNDS | Avidex Limited (GB) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004081011-A1 | IMMUNOMODULATING HETEROCYCLIC COMPOUNDS | AVIDEX LIMITED (GB) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312334-A1 | Immunomodulating Heterocyclic Compounds | CD40, CD40LG, NGFR | ACHE 3369/4885CA1 2084/4885CA2 2508/4885 |
| US-20160168408-A1 | SILVER INK | TP53, MKI67, NRAS | ACHE 2042/4885CA1 3304/4885CA2 3267/4885 |
| US-20080045527-A1 | Immunomodulating Heterocyclic Compounds | CD40, CD40LG, NGFR | ACHE 3369/4885CA1 2084/4885CA2 2508/4885 |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | CD40, CD40LG, NGFR | ACHE 3264/4885CA1 1652/4885CA2 2376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.